Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2014-09-12 Interim / Quarterly Rep…
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2014
2014-09-12 English
10-Q/A
Interim / Quarterly Report Q1 2014
2014-09-12 English
10-K/A
Annual Report FY 2013
2014-09-12 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. The content focuses on the Audit Committee's determination to restate previously issued financial statements for specific fiscal periods due to accounting issues related to preferred stock and derivative valuations. It discusses the restatement of financial statements for periods ended September 30, 2013, December 31, 2013, and March 31, 2014, and mentions consultation with auditors and the SEC staff. The document does not contain the full restated financial statements themselves but rather announces the decision and reasons for restatement. Given the nature of the filing as a current report announcing restatement and non-reliance on prior financial statements, it fits best under Regulatory Filings (RNS) rather than a full Annual Report (10-K), Audit Report (AR), or Interim Report (IR). The document length (7765 characters) and content support this classification as it is not a full financial report but a regulatory announcement of restatement.
2014-08-21 English
NT 10-Q
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the registrant, AmpliPhi Biosciences Corporation, is unable to file its quarterly report on Form 10-Q for the quarter ended June 30, 2014, within the prescribed time period. The document explains the reasons for the delay and requests additional time to complete the filing. This form is not the actual quarterly report (10-Q) itself but a notification about the late filing of that report. The document length is 4858 characters, which is relatively short and consistent with a notification rather than a full report. According to the rules, such a notification should be classified as a Regulatory Filing (RNS) because it is a regulatory announcement about the filing status and not the report itself.
2014-08-14 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a letter from AmpliPhi Biosciences Corporation to the SEC responding to staff comments on a previously filed Registration Statement on Form 10-12G/A. It discusses accounting treatments, valuation methods, and restatements related to preferred stock and derivatives. The document is a correspondence letter addressing regulatory comments rather than a financial report or announcement of results. It does not contain financial statements or detailed financial data but is a regulatory communication. The document length is 3795 characters, which is relatively short and consistent with a regulatory filing or comment letter. Therefore, it fits best under Regulatory Filings (RNS) as a response to SEC comments on a filing.
2014-08-12 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.